307 related articles for article (PubMed ID: 15494494)
1. Target antigens determine graft-versus-host disease phenotype.
Kaplan DH; Anderson BE; McNiff JM; Jain D; Shlomchik MJ; Shlomchik WD
J Immunol; 2004 Nov; 173(9):5467-75. PubMed ID: 15494494
[TBL] [Abstract][Full Text] [Related]
2. The immunological impact of genetic drift in the B10.BR congenic inbred mouse strain.
Fanning SL; Appel MY; Berger SA; Korngold R; Friedman TM
J Immunol; 2009 Oct; 183(7):4261-72. PubMed ID: 19752227
[TBL] [Abstract][Full Text] [Related]
3. Keratinocytes synthesize Ia antigen in acute cutaneous graft-vs-host disease.
Breathnach SM; Katz SI
J Immunol; 1983 Dec; 131(6):2741-5. PubMed ID: 6417231
[TBL] [Abstract][Full Text] [Related]
4. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Tedder TF; Fujimoto M
Blood; 2013 Apr; 121(16):3274-83. PubMed ID: 23422748
[TBL] [Abstract][Full Text] [Related]
5. Modulation of F1 cytotoxic potentials by graft-vs-host reaction. Cooperative non-H-2- and H-2D region-gene control of F1 natural resistance to graft-vs-host reaction-associated immunosuppression.
Ishikawa H; Saito K; Kubota E
J Immunol; 1989 Mar; 142(5):1495-9. PubMed ID: 2918225
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ.
Anderson BE; McNiff JM; Jain D; Blazar BR; Shlomchik WD; Shlomchik MJ
Blood; 2005 Mar; 105(5):2227-34. PubMed ID: 15522961
[TBL] [Abstract][Full Text] [Related]
7. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of graft-versus-host disease by double-negative regulatory T cells.
Young KJ; DuTemple B; Phillips MJ; Zhang L
J Immunol; 2003 Jul; 171(1):134-41. PubMed ID: 12816991
[TBL] [Abstract][Full Text] [Related]
9. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
10. Modeling Chronic Graft-versus-Host Disease in MHC-Matched Mouse Strains: Genetics, Graft Composition, and Tissue Targets.
Müller AMS; Min D; Wernig G; Levy RB; Perez VL; Herretes S; Florek M; Burnett C; Weinberg K; Shizuru JA
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2338-2349. PubMed ID: 31415899
[TBL] [Abstract][Full Text] [Related]
11. Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model.
Ilan Y; Gotsman I; Pines M; Beinart R; Zeira M; Ohana M; Rabbani E; Engelhardt D; Nagler A
Blood; 2000 Jun; 95(11):3613-9. PubMed ID: 10828052
[TBL] [Abstract][Full Text] [Related]
12. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens.
Korngold R; Leighton C; Mobraaten LE; Berger MA
Biol Blood Marrow Transplant; 1997 Jun; 3(2):57-64. PubMed ID: 9267665
[TBL] [Abstract][Full Text] [Related]
13. Effect of graft-versus-host disease on anti-tumor immunity.
Schreiber KL; Forman J
J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
[TBL] [Abstract][Full Text] [Related]
14. Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease.
Kim J; Kim HJ; Park K; Kim J; Choi HJ; Yagita H; Nam SH; Cho HR; Kwon B
Blood; 2007 Jul; 110(2):776-82. PubMed ID: 17363737
[TBL] [Abstract][Full Text] [Related]
15. Identification of a major susceptibility locus for lethal graft-versus-host disease in MHC-matched mice.
Cao TM; Lazzeroni LC; Tsai S; Pang WW; Kao A; Camp NJ; Thomas A; Shizuru JA
J Immunol; 2009 Jul; 183(1):462-9. PubMed ID: 19525392
[TBL] [Abstract][Full Text] [Related]
16. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease.
Anderson BE; McNiff JM; Matte C; Athanasiadis I; Shlomchik WD; Shlomchik MJ
Blood; 2004 Sep; 104(5):1565-73. PubMed ID: 15150080
[TBL] [Abstract][Full Text] [Related]
17. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.
Wu T; Young JS; Johnston H; Ni X; Deng R; Racine J; Wang M; Wang A; Todorov I; Wang J; Zeng D
J Immunol; 2013 Jul; 191(1):488-99. PubMed ID: 23709681
[TBL] [Abstract][Full Text] [Related]
18. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
19. Incompatibility for or pre-immunization against M1s determinants decreases lethal graft-versus-host reaction developed across non-H-2 and/or H-2 barriers.
Halle-Pannenko O; Festenstein H
J Immunogenet; 1981 Dec; 8(6):443-53. PubMed ID: 6174641
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
